Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate)

This study has been terminated.
(Clinical Hold)
The Cleveland Clinic
Duke Clinical Research Institute
Canadian VIGOUR Centre
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Regado Biosciences, Inc. Identifier:
First received: May 2, 2013
Last updated: October 22, 2014
Last verified: October 2014